Niva Bupa Q2 FY27 Earnings Call: H1 PAT Doubles To Rs. 273 Cr, Retail Market Share Rises To 11% (NIVABUPA)

Niva Bupa Health Insurance Company Ltd held its Q2 FY27 earnings call on November 04, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Retail-led growth doubles H1 PAT; market share gains continue

• H1 GWP of Rs.5,004 Cr, +26% YoY — excluding the "1 by N" industry impact; retail GWP grew 37% to Rs.3,800-odd Cr, lifting retail mix to 77% of the book from ~75% at end of Q1 FY 2026-2027.
• H1 PAT of Rs.273 Cr on the newly transitioned Ind AS basis — versus Rs.132 Cr in H1 FY 2025-2026; retail market share improved to 11% from 9.9% in H1 FY 2025-2026.
• CISR improved 365 bps to 99.5% in H1 FY 2026-2027 — management attributed this to a 78 bps expense-ratio reduction and a 287 bps claims-ratio reduction.
• Trailing four-quarter post-tax ROE of 13.8% — through Q2 FY 2026-2027; EOM at 34.7% in H1, below the 35% regulatory requirement plus allowances.
• Claim settlement rate of 95.6% in H1 FY 2026-2027 — up from 94.6% in H1 FY 2025-2026; blended NPS improved to 63 from 57.
• Reported retail health growth of 47% in H1 FY 2026-2027 — management cited the GST tailwind and the "1 by N" industry impact as continuing industry tailwinds.

Mix-driven improvement, not attachment gains; broker concerns rebutted

• Total loss ratio improved to 63.1% in H1 FY 2026-2027 from 65.9% — down ~300 bps YoY; the CFO corrected an analyst's claim that group claims ratio rose sharply, stating the group loss ratio has gone down, not up.
• Retail loss ratio of 67.4% in H1 FY 2026-2027 — improved 77 bps from ~68% in H1 FY 2025-2026; the CFO clarified the improvement is driven by business mix, not a substantial improvement in attachment loss ratios.
• Renewal book claims ratio running at circa 75% in Q2 FY 2026-2027 — stable with marginal improvement; fresh book improved versus history on better ticket sizes, higher sum insured mix and Reassure 3.0.
• Illustrative combined ratios of 102-103% (new business) vs 97-98% (renewal) — renewal is better on account of lower expenses; management said the incoming fresh book's age mix is not very different from earlier years.
• No one-offs in Q2 claims performance — the COO attributed the lower-than-anticipated loss ratio to multifactorial effects (infection rates over the last three years, growth, ticket-size and sum-insured mix) and said each factor cannot be delineated.
• Broker claims-payment concerns countered — responding to on-ground checks with 11 HNI insurance brokers (also flagging peers Star and Care), the MD & CEO said broker anecdotes should not be mixed with statistics, citing 47% H1 growth, improved retention and NPS; B2B/group is only 7-8% of the book with 98-99% settlement rates, while retail products carry higher rejection rates by design (waiting periods, two-year exclusions).

Draft commission norms create uncertainty; management sees market expansion

• Acquisition ratio at ~21% in Q2 FY 2026-2027 — the CFO corrected an analyst's 29% figure ("21 point something percent"); on where it moves under the regulator's proposed commission rates, management said it is too early to say, with mixed impact across channels including possible price decreases in channels such as affinity.
• Draft distribution norms cut commissions meaningfully — the analyst noted the regulator wants the savings passed on to policyholders via lower premiums or higher sum insured; management said it would certainly like to pass on benefits once regulations are in place, targeting mid-to-high teens ROE (period unspecified) with any excess passed to customers.
• Attachment volumes expected to hold or rise if the regulation goes through as is — value may decline; hospitalization cover addresses a key driver of loan delinquency, and partners are being aligned to protect consumers and loanees.
• PB (PolicyBazaar) growth may come down but continue at market growth rate — management is working with all partners on a new business model under the new regulations; it also cited the regulator's vision that lower commission with held prices lifts demand, as seen with GST.
• Management believes reform outcome will give "a significant steer" to volume growth — the CEO cited the GST experience as evidence that price elasticity of demand is "very real," and expressed confidence an answer working for distribution partners, customers and the company will be found, "as has been the case in the last one year."

Solvency trending down but comfortable; Rs.500 Cr debt headroom in place

• Solvency ratio of 2.03x as of 30 Sep 2026 under Indian GAAP — comfortably above the 1.50 regulatory minimum but trending down over the last 7-8 quarters; management attributed the H1 level partly to seasonality, as IGAAP profits concentrate in H2, especially Q4.
• Capital absorption from rapid growth — the required solvency margin is premium-driven (the CFO confirmed it is calculated on premium, not claims), and under IGAAP acquisition costs are recognized upfront, unlike Ind AS deferred acquisition cost.
• No equity raise required — management stated it is "very comfortable" with current solvency levels and holds board approval to raise debt capital of up to Rs.500 crore.
• RBC aligned with Ind AS expected "at some point in time" — management understands this from discussions with the regulator; Niva Bupa carries higher net worth under Ind AS and modeling has been done on both IGAAP and Ind AS bases, but management declined to quantify IFRS/RBC-based solvency until IRDAI releases its exposure draft or QIS.
• CISR of 98-99% to be sustained (period unspecified) — the MD & CEO said investors should continue to expect this, with expense management including acquisition costs the second lever alongside claims; the risk of a claims-based RSM becoming the binding constraint was called "too premature" to assess.

Yield holds at 7.4%; council standardization gains traction

• Annual investment yield (ex-ETF) of 7.4% in H1 FY 2026-2027 — on AUM of close to Rs.10,500 Cr, up versus full year FY 2025-2026 despite flattish equity markets and rising bond yields; the CFO said 7.4-7.5% is sustainable in the foreseeable future (period unspecified).
• Equity book at ~5.5% of AUM (ETF) as of Q2 FY 2026-2027 — market improvement expected to add to investment income; the portfolio is majorly at fair value, with government and corporate bonds (the major holding) classified as FVOCI and ETFs, AIFs and liquid funds as FVTPL.
• Common empanelment MOUs with more than 5,000 hospitals — as of the Q2 FY 2026-2027 call, with many thousands more in queue; the drive, under Dr. S. Prakash (CEO of Health Partnering within the Council), began with smaller/medium hospitals hitherto outside the insurance ambit.
• 8 infectious-disease protocols live, 18 more going live — out of the ICMR-defined Standard Treatment Workflows (segments cite 154 and 157 STWs); adoption will proceed in phases (timeline not specified), with position statements on robotic surgeries and immunotherapies already live.
• PPN network in 49 cities and 1,132 hospitals as of Q2 FY 2026-2027 — 22% of cashless claims in those hospitals routed to PPN; PPN hospitals are 15-20% less expensive like-for-like than tertiary/quaternary care facilities.

October momentum strong; growth outlook intact with caveats

• October 2026 (Q3 FY 2026-2027) overall and retail business grew in the 30s — despite the GST-exemption benefit now being in the base and a very strong October FY 2025-2026 base; the CFO expects this trend to continue going forward (period unspecified).
• Pricing actions to be informed by retail loss ratio — the CFO said pricing will be worked toward an overall combined ratio, and steady portfolio management is what analysts should continue to expect.
• Group B2B employer-employee business deliberately flat or degrowing — management is forgoing business where pricing does not support combined ratio requirements; the SME portion within employer-employee groups continues to grow robustly.
• Regulatory timing remains the key overhang — quantification of commission-norm impacts and RBC solvency effects awaits further clarity from the regulator (IRDAI exposure draft or QIS).
• No quantitative targets or time-bound guidance in the closing segment — the final queued question (Anshuman Deb, ICICI Securities) was skipped after the participant disconnected; the call concluded with Deepavali greetings.